MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
16.80
+0.25
+1.51%
After Hours: 16.95 +0.15 +0.89% 17:51 02/06 EST
OPEN
17.09
PREV CLOSE
16.55
HIGH
17.49
LOW
16.40
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
6.36
MARKET CAP
2.71B
P/E (TTM)
-4.5870
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DYN last week (0126-0130)?
Weekly Report · 5d ago
Dyne Therapeutics: 2026 Catalysts Point To Further Upside
Seeking Alpha · 01/27 09:07
Weekly Report: what happened at DYN last week (0119-0123)?
Weekly Report · 01/26 10:29
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate
Simply Wall St · 01/24 08:32
ClearBridge Small-Cap Growth trims Duolingo, Biohaven, QLYS; Adds PTGX, SSD, BETA, DYN in Q4
Seeking Alpha · 01/22 14:53
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Dyne Therapeutics (DYN)
TipRanks · 01/21 14:50
Dyne Therapeutics Price Target Cut to $16.00/Share From $17.00 by JP Morgan
Dow Jones · 01/20 15:26
Dyne Therapeutics Is Maintained at Neutral by JP Morgan
Dow Jones · 01/20 15:26
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Webull offers Dyne Therapeutics Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.